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Abstract
Human hepatic lipase (hHL) is mainly localized on the hepatocyte cell surface where it
hydrolyzes lipids from remnant lipoproteins and high density lipoproteins and promotes their
hepatic selective uptake. Furthermore, hepatic lipase (HL) is closely associated with obesity
in multiple studies. Therefore, HL may play a key role on lipid homeostasis in liver and white
adipose tissue (WAT). In the present study, we aimed to evaluate the effects of hHL expres-
sion on hepatic and white adipose triglyceride metabolism in vivo. Experiments were carried
out in hHL transgenic and wild-type mice fed a Western-type diet. Triglyceride metabolism
studies included β-oxidation and de novo lipogenesis in liver and WAT, hepatic triglyceride
secretion, and adipose lipoprotein lipase (LPL)-mediated free fatty acid (FFA) lipolysis and
influx. The expression of hHL promoted hepatic triglyceride accumulation and de novo lipo-
genesis without affecting triglyceride secretion, and this was associated with an upregula-
tion of Srebf1 as well as the main genes controlling the synthesis of fatty acids. Transgenic
mice also exhibited more adiposity and an increased LPL-mediated FFA influx into the WAT
without affecting glucose tolerance. Our results demonstrate that hHL promoted hepatic
steatosis in mice mainly by upregulating de novo lipogenesis. HL also upregulated WAT
LPL and promoted triglyceride-rich lipoprotein hydrolysis and adipose FFA uptake. These
data support the important role of hHL in regulating hepatic lipid homeostasis and confirm
the broad cardiometabolic role of HL.
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Introduction
Hepatic lipase (HL) is a lipase mainly secreted from the liver and localized mainly on the sur-
face of liver sinusoidal capillaries [1]. HL exhibits phospholipase A1 and triglyceride hydrolase
activities, thereby hydrolyzing the phospholipids and triglycerides of intermediate density, low
density lipoproteins (LDL) of large size and high density lipoproteins (HDL), and releasing
free fatty acids (FFA) and smaller lipoprotein particles [1, 2]. Beyond its lipolytic actions, HL
may also facilitate the selective uptake of HDL cholesteryl esters and the removal of apoB-con-
taining lipoprotein remnants via promoting their binding to cell-surface heparin sulphate pro-
teoglycans [1, 2].
Excessive intrahepatic triglyceride content, also termed steatosis, is the main feature of non-
alcoholic fatty liver disease (NAFLD), which occurs when the rate of hepatic fatty acid uptake
and de novo triglyceride synthesis are higher than the rate of fatty acid oxidation and hepatic tri-
glyceride secretion [3, 4]. Hepatic steatosis is directly related to enhanced oxidative stress and
lipotoxicity induced by excess fatty acids at the intracellular level [5]. Obesity is also associated
with the risk of NAFLD [6]. A significant association between HL and obesity has been found
in several human reports. Indeed, increased HL activity correlated with increased intra-abdomi-
nal fat in premenopausal women [7, 8], whereas reduced accumulation of intra-abdominal fat
was also correlated with reduced HL activity in men undergoing diet-induced weight loss [9].
Furthermore, HL activity positively correlated with the severity of steatosis in NAFLD patients,
even after correcting for body mass index and homeostasis model assessment (HOMA) for the
insulin resistance index [10]. Importantly, both liver HL activity and the amount of hepatic lip-
ids were significantly reduced in morbidly obese subjects after bariatric surgery [11].
Genetically-engineered mice for mouse HL have been used for investigating the effects of
HL deficiency on obesity and hepatic triglyceride accumulation [12–14]. Indeed, HL defi-
ciency prevented diet-induced obesity and steatosis without affecting glucose homeostasis
[12]. Nevertheless, in another study, HL deficiency promoted steatosis, inflammation, and glu-
cose intolerance [13]. It should be noted that mouse HL has a lower affinity for heparin sulfate
polysaccharides compared with that of human HL (hHL). Therefore, the mouse HL is mainly
found free in the circulation, whereas the human HL mainly remains anchored to liver proteo-
glycans [15]. A recent report showed that the expression of the catalytic activity of hHL was
able to reverse the lean phenotype of the former HL-deficient mice [14]. This rescue of body
fat gain seemed to be related to a reduced energy expenditure [14]. However, the specific path-
ways through which HL regulates triglyceride and fatty acid metabolisms remain largely
unknown.
This study aimed to evaluate the effects of hHL on hepatic and adipose tissue triglyceride
metabolic pathways in vivo. We show that overexpression of hHL in mice promoted hepatic
triglyceride accumulation mainly by upregulating the hepatic lipogenesis without affecting
hepatic triglyceride secretion. Furthermore, we also found that hHL expression upregulated
adipose-specific lipoprotein lipase (LPL), thereby increasing adipose FFA influx.
Materials and methods
Mice and diet
Wild-type (WT) and hHL transgenic mice in the C57BL/6J background were obtained from
Jackson Laboratories (#000664 and 003285, respectively, Bar Harbor, ME) [16]. The genotype
of the offspring was confirmed by polymerase chain reaction (PCR) using the WT and targeted
allele-specific primers recommended by Jackson Laboratories (https://www.jax.org/strain/
003285). All animal procedures were conducted in accordance with published regulations and
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reviewed and approved by the Institutional Animal Care Committee of the Institut de Recerca
of the Hospital de la Santa Creu i Sant Pau (Permit Number: 7083). Mice were kept in a tem-
perature-controlled (22˚C) room with a 12-hour light/dark cycle and food and water were pro-
vided ad libitum. For this study, we used eight- to nine-week-old male mice fed a Western-
type diet (TD.88137, Harlan Teklad, Madison, WI, containing 21% fat and 0.2% cholesterol)
for 16 weeks. Body weight and food intake were monitored. For studying triglyceride metabo-
lism under postprandial conditions, mice were administered an oral fat gavage consisting of
an intragastric load of 150 μL of olive oil and euthanized after 90 minutes (min), except for
hepatic triglyceride secretion studies, which use an inhibitor of lipolysis; therefore, assays were
carried out under fasting conditions to avoid the accumulation of intestinal triglyceride-rich
lipoproteins (see 2.5 section). Blood was obtained by cardiac puncture and serum obtained by
centrifugation at 10,000 g for 10 min at 4˚C. Tissues were collected, weighted, and immediately
frozen in liquid nitrogen for later use.
Lipid analyses and enzyme activities
Serum triglycerides, FFA, total serum cholesterol and phospholipids, and HDL lipids were
determined enzymatically using commercial kits adapted to a COBAS 6000 autoanalyzer
(Roche Diagnostics, Rotkreuz, Switzerland). Triglyceride determinations were corrected for
free-glycerol. Hepatic lipids were extracted with isopropyl alcohol-hexane (2:3, v:v) [17]. The
lipid layer was collected, evaporated, and resuspended in cholate 0.5% (w:v). Hepatic triglycer-
ides, total cholesterol, free-cholesterol, and phospholipids were determined using commercial
kits adapted to the COBAS 6000 autoanalyzer.
Liver and white adipose tissue (WAT) homogenates were obtained in a Polytron homoge-
nizer at 4˚C with a small piece of tissue in buffer EDH pH 7.4 [1 mM EDTA, 1 mM DTT, 10
mM HEPES, 5 U/mL heparin, plus three protease inhibitors: 0.5 mM PMSF, 4 μg/mL aproti-
nin, and 4 μg/mL pepstatin). Homogenates were centrifuged at 4˚C for 10 min at 1,000 g, and
the clear supernatants were used in the enzyme assay. LPL and HL activities were measured in
serum and tissues using a radiolabeled glycerol tri[9,10-(n)-3H]oleate emulsion (21.0 Ci/
mmol; Perkin Elmer, Waltham, MA) [18]. LPL was inactive in the HL assay due to the high
NaCl concentration [18].
Histology
Formalin-fixed livers and epididymal WAT (eWAT) were embedded in paraffin and samples
were sectioned at 5-μm for haematoxylin and eosin (H&E) staining [19]. Livers were embed-
ded in OCT compound, and 10-μm sections were cut on a cryostat. Tissue sections were
stained with Oil Red O for 2 min and counterstained with hematoxylin [20]. Adipocyte cross-
sectional area was determined using Image J software (available at http://rsbweb.nih.gov/ij/).
Determination of β-oxidation activity
Liver and eWAT were homogenized in a buffer composed of 150 mM NaCl, 1 mM dithiothrei-
tol, 30 mM EDTA, and 50 mM KH2PO4. β-oxidation activity was determined with 30 μg of
postnuclear supernatant by determining the conversion of palmitoyl CoA-1-14C into acetyl-
CoA [21].
De novo lipogenesis
Determination of de novo lipogenesis was performed after intraperitoneal (i.p.) injection of
10 μCi/g of 3H2O (Perkin Elmer, Waltham, MA). One hour later, animals were euthanized
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and blood and tissues obtained. The rate of incorporation of tritium from 3H2O into fatty
acids in the liver and eWAT was then determined (adapted from [22]). Briefly, tissues were
digested in 30% KOH at 70˚C for 10 min and saponification was performed by adding ethanol
(1:1, v:v) and incubating at 70˚C for 2 hours. Fatty acids were released by neutralizing with
H2SO4 6M and extracted three times with 5 mL of petroleum ether. The petroleum ether
extracts were dried and radioactivity was determined by liquid scintillation counting [22].
In vivo triglyceride secretion rate
Mice were bled to measure baseline plasma triglyceride concentration under fasting condi-
tions. Then, anesthetized mice were injected intravenously with Triton WR-1339 (Sigma-
Aldrich, St. Louis, MO) at a dose of 500 mg/kg dissolved in a 15% solution of 0.9% NaCl,
which inhibited lipolysis completely [23]. Blood was collected after the Triton injection and
plasma triglycerides were measured. Triglyceride accumulation in the serums 60 and 120 min
after injection was compared between mice of each genotype.
In vivo triglyceride-rich lipoprotein lipolysis and FFA uptake
The triglyceride-rich lipoproteins (TRL) (density 1.006 g/mL) were isolated by ultracentrifuga-
tion from serum of WT mice with an analytical fixed-angle rotor (Beckman Coulter, Fullerton,
CA, USA) and were radiolabeled with 40 μCi glycerol tri[9,10(n)-3H]oleate as previously
described [24]. Each mouse was intravenously injected with 500,000 cpm of the TRL fraction
in 100 μL of 0.9% NaCl and euthanized after 10 min. Radiolabeled liver and WAT triglycerides
were separated from FFA using methanol:chloroform:heptane 1.4:1.25:1 (v:v:v) and 0.1 M
H3BO3-KCO3 at pH 10.5 [24]. The radioactivity in the triglycerides and FFA fraction was
determined by liquid scintillation counting.
Glucose and insulin determination and glucose tolerance test
Serum glucose was determined enzymatically using a commercial kit adapted to a COBAS
6000 autoanalyzer (Roche Diagnostics, Rotkreuz, Switzerland) and serum insulin was assayed
by ELISA (Mercodia, Uppsala, Sweden). The HOMA-IR index was calculated by multiplying
the values of glucose (mM) and insulin (μU/mL) and dividing by 22.5. The glucose tolerance
test was performed by i.p. administration of glucose (1.3 mg/g of body mass) [17]. After that,
serum glucose was measured at t = 0, 15, 30, 60, 120, and 180 min. The area under the curve
(AUC) was calculated [17].
Quantitative real-time polymerase chain reaction analyses
Total RNA was extracted from liver and eWAT using TRIzol LS Reagent (Invitrogen, Carlsbad,
CA) following the manufacturer’s instructions and purified using an RNeasy Plus Mini Kit (Qia-
gen, Hilden, Germany). cDNA was generated using Oligo(dT)23 and dNTPs mix (Sigma-
Aldrich, St. Louis, MO) and M-MLV reverse transcriptase RNase H minus point mutant (Pro-
mega, Madison, WI) and it was subjected to quantitative real-time PCR amplification using Taq-
Man Master Mix (Promega, Madison, WI) and specific TaqMan probes (Applied Biosystems,
Foster City, CA) for acetyl-Coenzyme A carboxylase α (Acaca; Mm01304257_m1), acyl-Coen-
zyme A oxidase 1 (Acox1; Mm01246831_m1), apolipoprotein a1 (Apoa1; Mm 00437569_m1),
Apob (Mm01545159_m1), cluster of differentiation 36 (Cd36;Mm01135198_m1), carnitine pal-
mitoyltransferase 1a (Cpt1a; Mm00550438_m1), diacylglycerol O-acyltransferase 1 (Dgat1;
Mm00515643_m1), fatty acid synthase (Fasn; Mm01253292_m1), lecithin-cholesterol acyltrans-
ferase (Lcat; Mm00500505_m1), ldl receptor (Ldlr; Mm 00440169_m1), hormone-sensitive
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lipase expression (Lipe; Mm00495359_m1), lipoprotein lipase (Lpl; Mm00434764_m1), micro-
somal triglyceride transfer protein (Mttp; Mm00435015_m1), nuclear receptor subfamily 1,
group H, member 3 (Nr1h3; Mm00443451_m1), peroxisome proliferator activated receptor α
(Ppara; Mm00440939_m1), sterol regulatory element binding transcription factor 1 (Srebf1;
Mm01138344_m1), very low density lipoprotein receptor (Vldlr; Mm.PT.58.42530312 from
IDT) and 18S ribosomal RNA (Rn18s; Mm03928990_g1) as the internal control gene. Reactions
were run on a CFX96TM Real-Time System (Bio-Rad, Hercules, CA) according to the manufac-
turer’s instructions. Relative mRNA expression levels were calculated using the ΔΔCt method.
Statistical analyses
When data were normally distributed, the student’s unpaired t-test was used to compare dif-
ferences between groups; the nonparametric Mann–Whitney test was used for data that did
not follow the Gaussian distribution. The two-way ANOVA with Sidak’s multiple comparisons
test was used to compare differences among groups in serum lipids under fasting and post-
prandial conditions. The GraphPad Prism 6.0 software (GraphPad, San Diego, CA) was used
to perform all statistical analyses. A p value of< 0.05 was considered to indicate statistical
significance.
Results
Expression of human hepatic lipase increases animal weight and
promotes hepatic fat accumulation
To evaluate the effect of overexpressing hHL on diet-induced obesity and hepatic lipid accu-
mulation, we carried out a 16-week study comparing WT and hHL transgenic mice after high-
fat diet feeding, starting at eight to nine weeks of age. The body weight in the hHL-expressing
animals was higher than that in the WT group throughout the 16 weeks (Fig 1A). However, no
significant differences in food intake were found between mice of either genotype (Fig 1B).
After the 16-week feeding regimen, the livers of the hHL-expressing mice were pale in color as
compared to the healthy red color observed in the WT mice (Fig 1C). As expected, HL activity
was mainly present in the livers of hHL transgenic mice, whereas WT and hHL-expressing
mice showed similar basal levels of free HL in serum (Fig 1D). Consistent with the macro-
scopic changes found in the liver, the expression of hHL led to the development of steatosis as
revealed by the increased liver weight (Fig 2A) and a higher hepatic lipid content, mainly by an
increase of the triglyceride content (Fig 2B). These biochemical findings were confirmed by
histochemical evidence of marked macrovesicular steatosis in hHL-expressing mice compared
with the microvesicular steatosis pattern in WT mice (Fig 2C and 2D). The Oil Red O staining
showed that WT livers displayed some isolated patchy red staining (Fig 2E). Conversely, the
hHL transgenic mice livers showed widespread Oil Red O-positive macrovesicules (Fig 2F).
Expression of human hepatic lipase promotes hepatic triglyceride
lipogenesis without affecting triglyceride secretion or serum levels of
triglycerides
To elucidate the causes of the increased hepatic triglyceride levels found in hHL transgenic
mice, we studied whether these changes may be attributable to a defect in the rate of fatty acid
oxidation or a higher rate of de novo triglyceride synthesis combined with impaired hepatic tri-
glyceride secretion. However, the expression of hHL enhanced the hepatic rate of fatty acid
oxidation by 60% (Fig 3A), which was associated with the upregulation of several key peroxi-
some proliferator-activated receptor (PPAR)α target genes (such as Cpt1a and Acox1) involved
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in fatty acid β-oxidation without affecting Cd36 (Fig 3B). We then analyzed whether hHL
expression affected de novo lipogenesis in the livers of transgenic mice. The de novo lipogenesis
rate in the liver of transgenic mice was 2.5-fold higher than that of WT mice (Fig 4A). This
increase was also associated with significant increases in mRNA levels of hepatic Srebf1, Fasn,
and Acaca, but Nr1h3 which express liver X receptor α was not altered by hHL expression (Fig
4B). In contrast, the rate of in vivo hepatic triglyceride secretion and the expression of key genes
regulating very low density lipoprotein (VLDL) synthesis and assembly as well as hepatic tri-
glyceride secretion were not altered significantly by hHL expression (Fig 4C and 4D). Impor-
tantly, the hepatic expression of Apoa1, Ldlr and Vldlr was upregulated in hHL transgenic mice,
but not Lcat expression (S1 Fig). However, serum triglycerides and FFA under fasted or post-
prandial conditions were not significantly affected by the expression of hHL (Table 1).
Transgenic mice expressing human hepatic lipase exhibit more adiposity
and upregulated adipose-specific LPL and FFA influx
Transgenic mice displayed more adiposity than WT mice as shown in Fig 1C and as indicated
by the amount of fat mass stored in the epididymal, mesenteric, and perirenal fat pads (Fig
5A). Consistent with the body adiposity, the size of hHL eWAT adipocytes was increased com-
pared with that of WT adipocytes (Fig 5B), as shown histologically in Fig 5C and 5D. HL was
expressed at low levels in the eWAT of both transgenic and WT mice (Fig 1D). In contrast,
mice expressing hHL showed a higher expression of LPL in eWAT compared with that of
WT mice (Fig 5E). To determine the fate of triglyceride-derived fatty acids in WT and hHL
transgenic mice, we injected mouse TRL radiolabeled with [3H] triolein under postprandial
Fig 1. Overexpression of hHL in liver promotes diet-induced obesity and hepatomegaly. (A) Average
monthly weight in WT and hHL transgenic mice. (B) Food intake per day and per mouse was monitored over
48 hours in the last week of the 16-week feeding regimen. (C) Representative adipose fat and liver from both
WT and hHL transgenic mice. (D) Serum and tissue HL activities were measured using a radiolabeled glycerol
tri[9,10-(n)-3H]oleate emulsion. For A, B, and D, values are mean ± SEM of 6 WT and 8 hHL transgenic mice
and * indicates p <0.05 vs WT mice.
https://doi.org/10.1371/journal.pone.0189834.g001
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conditions. We reasoned that the adipose fat pads tissues with higher expression of LPL would
show the greatest increase in the triglyceride lipolysis and the uptake of radiolabeled FFA. Ten
min after the injection of radiolabeled TRL, we found a notable increase of radiolabeled FFA
into the different fat depots (Fig 5F), thereby suggesting that most of the label had undergone a
significant lipolysis and uptake. Furthermore, the expression of hHL did not have any impact
on de novo fatty acid synthesis in the adipose tissue, whereas the rate of fatty acid oxidation
was very low (S2 Fig). Additionally, Ldlr, Vldlr and Lipe expression was not altered in hHL
transgenic mice (0.59±0.11, 0.95±0.17 and 0.94±0.18, respectively, vs 1.00±0.24, 1.00±0.23 and
1,00±0.03, respectively, in WT mice).
Fig 2. Human HL overexpression promotes hepatic steatosis. (A) Liver weights after the 16-week feeding
experiment in hHL transgenic and WT mice. (B) Hepatic lipid levels of triglycerides (TG), esterified cholesterol
(EC), free cholesterol (FC), and phospholipids (PL) were determined after lipid extraction with isopropyl
alcohol-hexane. Values are mean ± SEM of 6 WT and 8 hHL transgenic mice and * indicates p <0.05 vs WT
mice. Representative liver tissue sections from WT (C) and hHL transgenic mice (D) stained with H&E.
Representative liver tissue sections from WT (E) and hHL transgenic mice (F) stained with Oil Red O. Livers
from hHL transgenic mice showed severe macrovesicular steatosis with positive staining for neutral lipids.
https://doi.org/10.1371/journal.pone.0189834.g002
Human hepatic lipase expression promotes steatosis and adiposity through different mechanisms
PLOS ONE | https://doi.org/10.1371/journal.pone.0189834 December 15, 2017 7 / 14
Discussion
Significant evidence indicates that hHL plays a key role on steatosis [10, 11]. Causality between
HL deficiency and hepatic fat accumulation has been studied in genetically-modified models
with divergent results [12, 13]. However, hHL is mainly bound to the cell surface of
Fig 3. Transgenic mice overexpressing hHL showed increased fatty acid β-oxidation. (A) Liver fatty
acid oxidation was determined as nmols of palmitoyl-CoA produced in both WT and hHL transgenic mice. B)
Transcriptional expression of hepatic Cd36 and the PPARα target genes Cpt1a and Acox1. Values are
mean ± SEM of 6 individual animals per group and * indicates p <0.05 vs WT mice.
https://doi.org/10.1371/journal.pone.0189834.g003
Fig 4. Expression of hHL promotes hepatic de novo lipogenesis without affecting triglyceride
secretion. (A) De novo synthesis of fatty acids in livers of hHL transgenic and WT mice. The incorporation of
3H2O into fatty acids was determined after i.p. injection of 10 mCi/kg of 3H2O into each mouse. Values are
mean ± SEM of 7 WT mice and 9 hHL transgenic mice. (B) Transcriptional expression of hepatic Nr1h3 and
the SREBP-1c target genes Fasn and Acaca (N = 6 mice/group). (C) In vivo triglyceride secretion rate in mice
injected intravenously with Triton WR-1339. Mice were bled immediately prior to Triton WR-1339 injection and
60 and 120 min afterwards. Triglycerides were measured and their change with respect to the baseline result
is shown (N = 3 mice/group). (D) Hepatic expression of Apob, Mttp, or Dgat1 (N = 6 mice/group). * indicates
p <0.05 vs WT mice.
https://doi.org/10.1371/journal.pone.0189834.g004
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hepatocytes, whereas the mouse form is mainly found circulating in the bloodstream [15].
This study demonstrates, for the first time to our knowledge, that hHL promoted hepatic tri-
glyceride accumulation mainly by increasing de novo triglyceride synthesis without affecting
its secretion from the liver. By hydrolyzing lipoprotein-associated phospholipids and triglycer-
ides, hHL may promote the uptake of FFA by the liver [25]. However, radiolabeled triglycer-
ide-rich lipoprotein-derived FFAs were not differentially accumulated in the livers of hHL
transgenic mice (S3 Fig). It should be noted that VLDL-triglyceride hydrolysis by HL is able to
activate both PPARα and β/δ through generation of specific monounsaturated FFAs [26].
Therefore, it is possible that the hHL-mediated increase in PPAR target genes and the higher
rate of β-oxidation could reduce the FFA available for triglyceride esterification, thus contrib-
uting to the unaltered triglyceride-rich lipoprotein-derived FFA levels that we found in the liv-
ers of our hHL transgenic mice. In contrast, hHL promoted hepatic de novo lipogenesis, which
is considered a prominent abnormality in NAFLD development [27]. Of note, hepatic steatosis
is usually associated to liver n-3 long-chain polyunsaturated fatty acid depletion, thereby lead-
ing to substantial enhancement in hepatic sterol regulatory element binding protein (SREBP)-
1c/PPARα ratio that favors de novo lipogenesis over fatty acid β-oxidation [28, 29]. In line with
these findings, we found that hHL upregulated the key enzymes involved in hepatic de novo
lipogenesis, which are mainly regulated by the SREBP-1c encoded by the Srebf1 gene [27].
Furthermore, PPARα may regulate positively the liver SREBP-1c target genes [30], as also
occurred for Ldlr and Vldlr ([31, 32]). However, the ability of the liver to increase the secretion
of triglycerides was rather reduced with respect to the increased hepatic de novo lipogenesis.
Taken together, our data clearly indicate that the upregulation of the hepatic de novo lipogene-
sis is the major contributor to the stored liver triglycerides in mice overexpressing hHL. The
low levels of VLDL and LDL and the high turnover of these lipoproteins in mice could have
limited the impact of liver Vldlr and Ldlr upregulation on postprandial serum triglycerides of
hHL transgenic mice [33, 34].
Rather surprisingly, hHL overexpression did not affect the HOMA-IR index and glucose
tolerance (S4 Fig), despite the fact that it increased body weight and fat mass. The absence of
any effect on glucose and insulin tolerance tests had been previously reported in HL-deficient
mice [12]. Importantly, hHL had a limited effect on systemic FFA and triglyceride levels in our
mice, as occurred in the HL-deficient mice fed the same Western-type diet [12]. These data
contrast with those of an independent study carried out in HL-deficient mice fed a diet with a
higher level of cholesterol that exhibited enhanced systemic inflammation, glucose intolerance,
and higher FFA and triglyceride levels [13], thereby suggesting that the HL-mediated effect on
Table 1. Serum lipids and lipoproteins in WT and hHL transgenic mice fed a Western diet for 16 weeks under fasting and postprandial conditions.
Fasting conditions Postprandial conditions
WT hHL WT hHL
Serum triglycerides (mM) 0.25 ± 0.07 0.39 ± 0.03 0.72 ± 0.11a 0.50 ± 0.08
Serum FFA (mM) 1.04 ± 0.07 1.16 ± 0.06 0.62 ± 0.05 a 0.67 ± 0.03 a
Serum cholesterol (mM) 5.13 ± 0.28 4.87 ± 0.30 6.40 ± 0.25 a 6.50 ± 0.47 a
Serum phospholipids (mM) 4.12 ± 0.11 4.20 ± 0.11 5.32 ± 0.13 a 4.73 ± 0.33
HDL cholesterol (mM) 4.42 ± 0.43 3.89 ± 0.22 5.07 ± 0.23 4.81 ± 0.33
HDL phospholipids (mM) 3.91 ± 0.10 3.90 ± 0.09 4.65 ± 0.14a 4.06 ± 0.28b
Values are mean ± SEM of 6 mice per group. Two-way ANOVA was used to compare differences among groups under fasting and postprandial conditions.
ap < 0.05 vs WT and
bp < 0.05 vs fasting conditions.
https://doi.org/10.1371/journal.pone.0189834.t001
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glucose homeostasis requires an exacerbated inflammatory and dyslipidemic state, at least in
mice. Of note, a direct association between hepatic steatosis and HL was found in NAFLD
patients, even after controlling for insulin resistance [10], thus suggesting that insulin resis-
tance seems to be secondary to the HL-mediated effects on steatosis.
Our data also demonstrated a stimulating effect of hHL on adipocyte LPL. This finding
might suggest an increased release and uptake of FFA from circulating TRLs into adipocytes,
which in turn might help to explain fat accumulation in these mice. The elevated proportion of
radiolabeled FFA-to-triglycerides in adipose tissue of transgenic mice would support this
hypothesis. It should be noted that hHL was not expressed in WAT, and neither did we find
any alteration in the rate of β-oxidation or the regulation of de novo lipogenesis. In contrast,
Fig 5. HL transgenic mice exhibit more adiposity and upregulated adipose LPL-mediated FFA influx.
(A) Fat pad mass weights after the 16-week feeding experiment in hHL transgenic and WT mice. Each value
represents the mean ± SEM of data from 6 WT mice and 8 hHL transgenic mice. (B) Quantitation of adipocyte
size (N = 3 mice/group). Representative photomicrographs of H&E stained sections from eWAT of WT (C)
and hHL transgenic mice (D). (E) Transcriptional expression of eWAT Lpl and tissue activity (N = 5 mice/
group). (F) [3H]-triglyceride labeled triglyceride-rich lipoproteins were injected intravenously into WT and hHL
transgenic mice under postprandial conditions and radiolabeled FFA and triglycerides were measured in WAT
fat pads. Radiolabeled triglycerides + FFA in the collected fat depots did not differ between genotypes
(0.92 ± 0.05 vs 0.80 ± 0.16% of the injected dose in WT and hHL transgenic mice, respectively). [3H]FFA/
triglyceride ratios are shown (N = 3 mice/group). * indicates p <0.05 vs WT mice.
https://doi.org/10.1371/journal.pone.0189834.g005
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hHL is expressed in mouse adrenal cortex [35], and HL plays a key role in adrenal cholesterol
delivery for steroid synthesis [36]. Although the effects of hHL on mouse adrenal response
have not been investigated, it is possible that an enhanced adrenal corticosterone response [36]
could upregulate LPL in eWAT [37, 38].
In the present study, the expression of hHL in transgenic mice had a limited impact on
HDL lipid levels. The upregulation of liver Apoa1 may have counterbalanced the HDL choles-
terol-lowering effects of hHL. The absence of changes in HDL cholesterol levels had been pre-
viously reported in mice overexpressing HL at moderately high levels (up to 3-fold) [14, 16],
but a contrast with the severe HDL deficiency showed when transgenic mice were fed a high-
fat diet containing sodium cholate [35]. The discrepancy among these studies may be related
to the different dietary regimens and the degree of HL expression, since the latter used a diet
that induced proinflammatory and hepatotoxic effects and HL activity was 20-fold higher than
that of non-transgenic mice [35].
In conclusion, our study demonstrates that hHL promoted hepatic steatosis in mice
mainly by upregulating de novo lipogenesis without affecting hepatic triglyceride secretion
and glucose homeostasis. The expression of hHL also promoted obesity and upregulated the
adipose LPL-mediated FFA influx. Therefore, our data support the critical role of hHL in
regulating hepatic triglyceride accumulation and its key influence on adipose tissue triglycer-
ide homeostasis.
Supporting information
S1 Fig. Hepatic expression of Apoa1, Ldlr and Vldlr is upregulated in hHL transgenic mice.
Transcriptional expression of hepatic Apoa1, Lcat, Ldlr and Vldlr. Values are mean ± SEM of 6
individual animals per group and  indicates p<0.05 vs WT mice.
(TIF)
S2 Fig. Transgenic mice overexpressing hHL do not show any alteration in eWAT fatty
acid β-oxidation and de novo fatty acid lipogenesis. (A) Epididymal WAT fatty acid oxida-
tion was determined as nmols of palmitoyl-CoA produced in both WT and hHL transgenic
mice under postprandial conditions. Values are mean ± SEM of 2 WT mice and 6 hHL trans-
genic mice. (B) The transcriptional expression of eWAT PPARα target genes Cpt1a and Acox1
(N = 6 mice per group). (C) De novo synthesis of fatty acids in eWAT of hHL transgenic and
WT mice. Mice were i.p. injected with 10 mCi/kg of 3H2O and sacrificed one hour later. The
incorporation of 3H2O into fatty acids was determined after lipid extraction of the tissues with
petroleum ether. Values are mean ± SEM of 7 WT mice and 9 hHL transgenic mice. (D) The
transcriptional expression of SREBP-1c target genes Fasn and Acaca (N = 6 mice per group).
(TIF)
S3 Fig. Triglyceride-rich lipoprotein-derived FFAs are not accumulated in the livers of
hHL transgenic mice. [3H]-triglyceride labeled triglyceride-rich lipoproteins were injected
intravenously into WT and hHL transgenic mice under postprandial conditions and radiola-
beled FFA and triglycerides were measured in the livers of the same animals used in the Fig 5F.
(TIF)
S4 Fig. Effects of hHL expression on insulin resistance. (A) Fasting serum glucose levels. (B)
The homeostatic model assessment for insulin resistance (HOMA-IR). (C) Glucose kinetics
following an intraperitoneal glucose tolerance test (IPGTT). (D) Area under the curve (AUC)
of glucose after IPGTT. Values are mean ± SEM of 6 individual animals per group.
(TIF)
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